Remission of congenital multi-system type langerhans cell histiocytosis with chemotherapy

Kosuke Tamefusa, Hisashi Ishida, Kana Washio, Toshiaki Ishida, Hirosuke Morita, Akira Shimada

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Patients with multi-system (MS)-type langerhans cell histiocytosis (LCH) show poor outcomes, especially congenital MS LCH cases were shown in high mortality rate. We experienced a congenital case of MS LCH with high risk organs, who needed intensive respiratory support after birth. Even though intensive chemotherapy was discontinued, this patient's lung LCH lesions gradually became reduced and his respiratory condition recovered; therefore, we restarted and completed maintenance chemotherapy. The patient maintained complete remission for more than 4 years after the end of chemotherapy. Our case suggests that congenital MS LCH even with severe organ involvement can be treated successfully with chemotherapy.

Original languageEnglish
Pages (from-to)61-65
Number of pages5
JournalActa medica Okayama
Issue number1
Publication statusPublished - 2019


  • Congenital
  • Langerhans-cell histiocytosis
  • Multisystem type

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Remission of congenital multi-system type langerhans cell histiocytosis with chemotherapy'. Together they form a unique fingerprint.

Cite this